What is the price-to-earnings ratio of Alliance Pharma?
The price-earnings ratio of Alliance Pharma is currently 1.08.
Alliance Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Comparing Alliance Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
The P/S ratio is instrumental for investors evaluating Alliance Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Variations in Alliance Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
The price-earnings ratio of Alliance Pharma is currently 1.08.
The price-to-earnings ratio of Alliance Pharma has increased by -41.3% fallen (meaning "decreased" or "dropped") compared to last year.
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Yes, the price-to-earnings ratio of Alliance Pharma is high compared to other companies.
An increase in the price-earnings ratio of Alliance Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
A decrease in the price-earnings ratio of Alliance Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
Some factors that influence the price-earnings ratio of Alliance Pharma are the company's growth, financial position, industry development, and the overall economic situation.
Over the past 12 months, Alliance Pharma paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 5.54 %. For the coming 12 months, Alliance Pharma is expected to pay a dividend of 0.02 GBP.
The current dividend yield of Alliance Pharma is 5.54 %.
Alliance Pharma pays a quarterly dividend. This is distributed in the months of January, July, January, July.
Alliance Pharma paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 5.59 %.
Alliance Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Alliance Pharma from 7/18/2023 amounting to 0.012 GBP, you needed to have the stock in your portfolio before the ex-date on 6/22/2023.
The last dividend was paid out on 7/18/2023.
In the year 2023, Alliance Pharma distributed 0.017 GBP as dividends.
The dividends of Alliance Pharma are distributed in GBP.
The Alliance Pharma stock can be added to a savings plan with the following providers: Trade Republic
Our stock analysis for Alliance Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alliance Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.